Copenhagen, Denmark | March 23, 2026
New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb) demonstrates high long-term treatment persistence among Alzheimer’s disease patients in the United States, reinforcing its role as a disease-modifying therapy in clinical practice. The data, jointly reported by Eisai and Biogen, provides critical insights into patient adherence, dosing patterns, and long-term clinical utility of this anti-amyloid monoclonal antibody.
Real-World Evidence Confirms Sustained Patient Adherence
The analysis, based on the PurpleLab® CLEAR Claims database, evaluated over 10,000 patients receiving intravenous lecanemab between 2023 and 2025, making it one of the largest real-world datasets for Alzheimer’s treatment persistence. The findings showed that 78.4% of patients remained on therapy at 18 months, with 71.7% continuing at 20 months and 67.3% at 24 months, demonstrating strong long-term adherence in routine clinical practice.
Importantly, this is the first real-world study reporting persistence beyond 18 months, a key milestone given that Alzheimer’s disease requires chronic, sustained treatment strategies. The results suggest that treatment interruptions due to monitoring requirements or adverse events did not significantly impact adherence, indicating favorable real-world feasibility.
Clinical Outcomes Supported by Long-Term Treatment Continuation
Advertisement
The persistence data aligns with earlier Phase 3 findings, where 94% of patients completing 18 months of treatment opted to continue into long-term extension studies, highlighting strong patient and clinician confidence in therapy continuation.
Long-term follow-up data further indicate that patients receiving lecanemab for up to four years experienced sustained clinical benefits, including reduced cognitive decline compared to the natural progression of Alzheimer’s disease. These outcomes reinforce the importance of continuous treatment adherence in achieving meaningful disease modification.
Baseline patient characteristics in the real-world study—including a mean age of 73.8 years and common comorbidities such as hypertension and dyslipidemia—closely mirrored those observed in controlled clinical trials, supporting the external validity and generalizability of the findings.
Implications for Clinical Practice and Regulatory Landscape
The demonstrated high treatment persistence and adherence rates have significant implications for clinical practice, patient management, and regulatory evaluation. In chronic neurodegenerative diseases like Alzheimer’s, long-term adherence is directly linked to improved outcomes, reduced disease burden, and enhanced patient satisfaction.
From a regulatory and lifecycle management perspective, these findings strengthen the real-world evidence (RWE) profile of LEQEMBI, supporting its continued global adoption and potential label expansion strategies. The therapy is already approved in more than 50 countries, with ongoing regulatory activities including supplemental applications and new formulation developments, further highlighting its evolving role in Alzheimer’s treatment.
Additionally, the consistency between real-world dosing patterns and recommended clinical protocols confirms that the therapy can be effectively implemented in standard healthcare settings without significant deviations, a key consideration for Good Clinical Practice (GCP) and post-marketing surveillance frameworks.
The AD/PD 2026 findings position LEQEMBI as a leading Alzheimer’s therapy with strong real-world adherence and long-term clinical benefit, addressing a critical unmet need in neurodegenerative disease management. The high persistence rates, sustained efficacy signals, and alignment with clinical trial data underscore its value as a disease-modifying treatment supported by robust real-world evidence.
Source: Eisai and Biogen press release
